USAMRIID’s Ebola Virus Research

Agency: 
Dept. of Defense

The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) has developed a plaque assay that quantifies virus particles in research samples in a Biosafety Level 4 (BSL-4) training suite. BSL-4, the highest level of biocontainment, is required to safely study the world’s most hazardous viruses, including Ebola. USAMRIID investigators significantly contributed to the vaccines, therapeutics, and diagnostics used in the recent—and devastating—Ebola virus disease outbreaks in Africa. Currently, the Institute has 98 agreements with industry, academia, and other government agencies to continue developing medical countermeasures against Ebola and related viruses that pose a threat to U.S. and global health.

USAMRIID provides leading edge medical capabilities to defend against current and emerging biological threats. USAMRIID’s research leads to vaccines, drugs, diagnostics, information, and training programs that benefit military and public health. The Institute plays a key role in medical biodefense research as the only Department of Defense laboratory studying highly hazardous viruses, like Ebola, that require maximum containment at Biosafety Level 4.
 

Category: 
Lab Spotlight
Region: 
Mid-Atlantic